The alliance between Novo Nordisk and telehealth company Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony. In a statement, Novo Nordisk said that it was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback